Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at α2-adrenoceptors II. Description of a xanthine-dependent enzymatic activity in spleen cytosol

Biochemical Pharmacology

Volumn 56, Issue 9, 1998, Pages 1121-1128

  Dambrova, Maija ^a   Uhlén, Staffan ^a   Welch, Christopher J ^a   Prusis, Peteris ^a   Wikberg, Jarl E S ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Metabolic conversion; N hydroxyguanidine, guanoxabenz; Reduction; spleen; Xanthine oxidase

Indexed keywords

ALLOPURINOL; ALPHA 2A ADRENERGIC RECEPTOR; GUANABENZ; GUANOXABENZ; XANTHINE OXIDASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; REDUCTION; SPLEEN CELL;

EID: 0031796057     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00136-1     Document Type: Article

References (21)

1. 2-adrenoceptors in the kidney. Br J Pharmacol 104: 657-664, 1991.
2. 2 A-adrenoceptors in the rat. Naunyn-Schmiedebergs Arch Pharmacol 347: 280-288, 1993.
3. 2B-adrenoceptors in the rat. Pharmacol Toxicol 72: 40-49, 1993.
4. 2? In: Adrenoceptors (Ed. RR Ruffolo), pp. 109-118. Harwood Academic Publishers, Luxembourg, 1995.
5. 2-adrenoceptors. I. Description of an enzymatic activity in spleen membranes. Biochem Pharmacol 56: 1111-1119, 1998.
6. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
7. 2-adrenoceptor. Br J Pharmacol 106: 986-995, 1992.
8. De Lean A, Hancock AM and Lefkowitz RJ, Validation and statistical analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharm 21: 5-16, 1982.
9. 2-adrenoceptors. Acta Pharmacol Toxicol 59: 270-278, 1986.
10. 2A-selective compound. Eur J Pharmacol 202: 235-243, 1991.
11. 1-aminoguanidines. Drug Res 42: 65-69, 1992.
12. Massey V, Komai H and Palmer G, On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 245: 11, 2837-2844, 1970.
13. Hille R and Massey V, Tight binding inhibitors of xanthine oxidase. Pharmac Ther 14: 249-263, 1981.
14. Wikberg JES, Dambrova M, Uhlén S and Prusis P, Conditions for biphasic competition curves in radioligand binding for ligands subjected to metabolic transformation. Biochem Pharmacol 56: 1129-1137, 1998.
15. Hui MB, Lien EJ and Trousdale MD, Inhibition of human adenoviruses by 1-(2′-hydroxy-5′-methoxybenzylidene) amino-3-hydroxyguanidine tosylate. Antiviral Res 24: 261-73, 1994.
16. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J and Gallo RC, Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science (Washington DC) 266: 801-805, 1994.
17. Chern J-W, Leu Y-L, Wang S-S, Jou R, Lee C-F, Tsou P-C, Hsu S-C, Liaw Y-C and Lin H-M, Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. J Med Chem 40: 2276-2286, 1997.
18. Walker JB and Walker MS, The enzymatic reduction of hydroxyguanidine. J Biol Chem 234: 1481-1484, 1959.
19. Clement B, Schultze-Mosgau M-H and Wohlers H, Cytochrome P450 dependent N-hydroxylation of guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite. Biochem Pharmacol 46: 2249-2267, 1993.
20. Clement B, Demesmaeker M and Line S, Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylate metabolite: Characterization of the two reactions and genotoxic potential of guanoxabenz. Chem Res Toxicol 9: 682-688, 1996.
21. Clement B and Demesmaeker M, Formation of guaoxbenz from guanabenz in human liver. A new metabolic marker for CYP1A2. Drug Metab Disp 25: 1266-1271, 1997.